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Abelson  murine leukemia virus  (A-MuLV)'  causes  a  rapidly  progressive 
lymphosarcoma which does not involve the thymus (1). The tumor appears to 
originate in the bone marrow, the site of first detectable pathological changes 
after virus infection (2). The tumors are probably composed of cells related to 
bone marrow-derived cells (B cells) because some of the tumors have immuno- 
globulin on their surface (3, 4). The tumor cells all lack 0-antigen (3), an antigen 
found on thymic tumors (5). 
Scher and Siegler (6) have shown that A-MuLV directly transforms NIH/3T3 
fibroblastic cells in vitro. They derived a nonproducer A-MuLV transformed cell 
line thus demonstrating that A-MuLV is defective for replication and requires a 
helper virus, such as Moloney leukemia virus (M-MuLV), to replicate. 
Sklar et al.  (7) and Raschke et al.  (8) have infected short-term (3-6 days) 
cultures of  mouse splenocytes with A-MuLV and have shown that after inocula- 
tion into animals, the cultured cells developed into lymphoid tumors. Animal 
inoculation  was  required  for  transformation  to  be  recognized  in  these  systems. 
A-MuLV  infection  of  fetal  liver  cells  in vitro  has been shown to induce the 
continuous growth of  populations  of  cells  with lymphoid morphology (9).  These 
lymphoid cells  have been maintained in culture  for  more than 300 generations 
and are malignant because they cause rapidly  invasive lymphoid tumors in 
animals. A-MuLV is therefore  able to carry out in vitro  the transformation of 
lymphoid cells. 
We now report  the development of  a semisolid  agarose transformation assay 
(10)  which allows  recognition  of  foci  of  transformed  lymphoid cells.  Using this 
system, the number of  lymphoid cell  colonies  produced was shown to depend 
linearly  on the concentration  of  A-MuLV. The assay system has been used to 
study the distribution  of  A-MuLV-sensitive target  cells  in lymphoid organs of 
fetal  and neonatal mice and to study the susceptibility  of  different  strains  of 
mice to  A-MuLV-induced transformation. 
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Materials and Methods 
Cell Preparation.  Fetal liver cell cultures were prepared from the livers of embryos of 12-20- 
day-pregnant mice. Spleen and thymus cultures were prepared from 3-5-wk-old mice. All tissues 
were forced through a stainless steel mesh (Falcon Plastics, Division of BioQuest, Oxnard, Calif.), 
and the cells were suspended in RPMI-1640 medium (Grand Island Biological Company, Grand 
Island, N. Y.) containing 20% fetal calf serum (Microbiological Associates, Bethesda, Md.) (heat 
inactivated at 56°C for 30 min) and 2-mercaptoethanol (Aldrich Chemical Co., Inc., Milwaukee, 
Wis.) at a final concentration of 50/~M. Bone marrow cell cultures were prepared from the marrow 
of 3-5-wk-old mouse femurs and tibias.  The marrow plugs were removed using a  syringe and 
suspended in RPMI-1640 medium. For experiments involving variations in culture medium, all 
cell suspensions were prepared in phosphate-buffered saline (PBS) medium (200 mg/liter KC1, 200 
mg/liter KH2PO4,  100 rag/liter MgC12"  6H20, 8,000 rag/liter NaC1, 1,150 mg/liter Na2HPO4.2H20, 
supplemented with 2% heat-inactivated fetal calf serum). Aliquots of the cell pools were collected 
by centrifugation at low speed and resuspended in the test medium. Cell viability was monitored 
by the exclusion of 0.05%  trypan blue. 
Agarose Transformation  Assay.  Virus stocks of A-MuLV and M-MuLV and conditioned me- 
dium have been described (9).  2 million nucleated cells were suspended in 1 ml of medium and 
treated with 1 ml of virus stock,  conditioned medium,  or fresh medium.  Virus adsorption was 
carried out in 13 x 100-ram glass test tubes in the presence of 4 ~g/ml polybrene (Aldrich Chemical 
Co., Inc.) at 37°C in a humidified 5% CO2 atmosphere. Tubes were agitated every 15 min. After a 
2.5 h adsorption period, the cells were mixed with agarose medium containing RPMI-1640 in 0.3% 
agarose (Type II, Sigma Chemical Co., St. Louis, Mo.) supplemented with 20% fetal calf sernm, 50 
~M mercapteethanol, and 2/~g/ml polybrene final concentration. 1 million cells were plated in 30- 
mm plastic Petri dishes (A]S Nunc, Vanguard International, Red Bank, N. J.) in a total volume of 
2 ml of agarose medium. Cultures were incubated and fed 1 ml of agarose medium at 5 and 10 days 
postinfection. Macroscopically visible colonies were scored 12 days postinfection. 
Clones of Transformed Cells.  Foci of transformed cells were removed from agarose 10-18 days 
postinfection using a  Pasteur pipette, smeared on slides and stained with Wright-Giemsa stain 
(Harleco, Philadelphia,  Pa.) for microscopic examination.  Clones were also removed, washed in 
PBS medium to remove any contaminating agarose, and treated with goat antimouse IgG and IgM 
(Meloy Laboratories,  Springfield,  Va.)  as  described  (9).  To  subculture  the  clones,  foci were 
removed and plated in 2 ml of liquid RPML1640 medium in 30-mm plastic dishes. Cultures were 
monitored for cell growth. When the cells reached a density of 5 ×  105-1 ×  10  e cells/ml they were 
transferred at a  1:2 split ratio. After an initial period of about 1 mo during which cell densities 
were maintained between 1-2 × 10  ~ and I  × 10  e cells/ml, the cell population doubled every 12-15 h 
and could be passaged at split ratios of 1:100 every 3-4 days. Such cells have been maintained in 
continuous culture in excess of 300 generations. 
Viral Studies.  The presence of both the focus-forming and plaque-forming components of A- 
MuLV in transformed clones was tested using the NIH/3T3 transformation assay (6) and the XC 
plaque assay (11). Feci of transformed lymphoid cells were removed from agarose with a Pasteur 
pipette and added to indicator layers of NIH/3T3 cells. Foci of transformed NIH/3T3 cells were 
scored 13-15 days postinfection. After the foci were scored, the dishes were irradiated and overlaid 
with XC cells in standard fashion. 
Discontinuous Bovine Serum Albumin Gradients.  Fractionation of mouse bone marrow cells 
was  carried  out  by  centrifugation  on  discontinuous  bovine  serum  albumin  (BSA)  gradients 
according to Dicke et al. (12). The gradient was prepared by sequentially layering 1-ml aliquots of 
BSA solutions in 2% decreasing concentration from 33 to 19% into a 16 x 125-ram plastic test tube 
(Falcon Plastics). BSA solutions were prepared as described by Kung et al. (13). Bone marrow cells 
from BSA fractionation were harvested in PBS medium. The cells were collected by centrifugation 
at low speed and resuspended in 17% BSA before layering on top of the gradient. The gradient was 
centrifuged at 1,500g for 30 rain at 6°C in an International model PR-J centrifuge using the no. 269 
rotor (International Equipment, Needham Heights, Mass.).  Cell fractions forming at the inter- 
faces of the BSA solutions were removed using a Pasteur pipette and washed with PBS. The cell 
fractions were resnspended in RPMI-1640 medium, counted, and adjusted to 2 × 10  s cells/ml before 
virus adsorption. Cell fraction 1 was between 17-19% layers, fraction 2 between 19-21% layers, etc. 
Mice.  NIH/Swiss mice, originally obtained from the Division of Research Services, Veterinary NAOMI  ROSENBERG AND  DAVID BALTIMORE  1455 
Resources  Branch, National Institutes of Health,  Bethesda,  Md.,  were raised in our colony; 
BALB/c mice were either raised in our colony or purchased from Charles River Breeding Labora- 
tory, Willmington, Mass. A/J, NZB/BINJ, C57L/J,  C57B1R¢cdJ, SWR/J, DBA/2J,  and DBA/1J 
mice were purchased from The Jackson Laboratory, Bar Harbor, Maine. C57BL/6 mice were 
purchased from West Seneca Laboratories, West Seneca, New York.  Nude mice were obtained 
from Dr. J. Beard, Life Sciences, Inc., St. Petersburg, Fla. 
Results 
Agarose Transformation Assay.  To quantitate the transformation process, 
an assay which allows recognition of single transformation events has been 
developed using a semisolid agarose culture system. For this assay, bone mar- 
row cells were infected in suspension in RPMI-1640  medium. After a  2.5  h 
adsorption period,  the  cells were mixed with  agarose  medium and  plated. 
Cultures were checked to insure the absence of clumps of cells. 
Microscopic  colonies of 25-500 cells appeared in both control and infected 
cultures 3-5 days after plating. The number of colonies varied from 300-500/ 
plate. These are presumably the same type of colonies reported by Metcalf  et al. 
(14) and do not appear related to the presence of A-MuLV. 
In plates of cells infected with A-MuLV, colonies appeared that grew progres- 
sively and became macroscopically visible (1-2 mm in diameter) by 10-12 days 
postinfection (Fig.  1). The number of visible colonies did not increase after this 
time, although most of the colonies continued to increase in size if the feeding 
schedule was extended. No macroscopic colonies were seen in control cultures or 
cultures infected with M-MuLV alone. The microscopic colonies in the control 
and M-MuLV-infected cultures began to die 7-10 days after plating. 
Colonies of Transformed  Cells.  Colonies from A-MuLV-infected cultures 
were transferred with a Pasteur pipette to microscope slides and stained with 
Wright-Giemsa stain. Light microscope examination showed that the loci were 
composed of cells of lymphoid morphology (Fig. 2). The cells had a large nucleus 
with a poorly defined nucleolus. The scant cytoplasm contained no granules but 
was frequently vacuolated. Mitotic figures were observed. Although the size of 
the foci varied, the morphology  of  the cells was uniform from colony to colony. 
Both  large and small foci were removed from agarose and tested for the 
presence of surface immunoglobulin. The cells were washed with PBS medium 
to remove the agarose and treated with goat antimouse IgG and IgM. None of 
the cells in the 20 colonies tested had immunoglobulin on their surface detecta- 
ble by this assay. 
Many of the foci could be transferred from agarose with a Pasteur pipette and 
grown in RPMI-1640 medium. Colonies that become permanent cell lines reach 
densities of 5 ×  105-1 ×  10  e cells/ml by 10-14 days after transfer from agarose. 
Cells from colonies that do not grow continuously in liquid medium do not 
increase in  number significantly ai~r transfer.  Colony size in agarose was 
related to the ability of the cells to replicate continuously in liquid medium. 
Greater than 90% of the larger colonies could be maintained by serial passage, 
while only 20-40% of the smaller foci became established cell lines. 
Optimum Conditions for Transformation.  The dependence of A-MuLV-in- 
duced transformation on the concentration of several components in the assay 
mixture was studied. For these experiments pools of bone marrow cells were 1456  ABELSON  VIRUS  LYMPHOID  CELL  TRANSFORMATION  ASSAY 
FIG. I.  Agarose transformation assay plates.  (A,  plate  on  left)  Bone marrow culture  15  days 
after  infection  with A-MuLV.  (B,  plate  on right)  Control bone marrow culture 15  days after 
plating. 
prepared in PBS medium, aliquoted,  and centrifuged  at low speed. The cells 
were  then  suspended in  the  various  test  media.  This  procedure did  not  affect  cell 
viability.  Transformation frequency was  dependent  on  the  concentration  of  fetal 
calf  serum in the incubation medium,  with concentrations of  less  than 20% 
resulting  in  fewer  loci  (Table  I).  Foci  in  cultures  maintained at  10% serum were 
also  much smaller than those in  cultures  maintained in 15 and 20% serum. 
Mercaptoethanol was required  for  transformation in  this  system. 50 ~M was 
the optimum concentration  with 10-fold  increases  or  decreases  resulting  in  100- 
fold  reductions  in  transformation frequency. 
Use of polybrene to enhance virus infectivity (15) increased the transforma- 
tion frequency by approximately 5-fold. The presence ofpelybrene in the adsorp- 
tion  and  incubation medium at  the  concentrations used  did  not  affect cell 
viability. 
Agarose was a  more efficient supporting medium for transformation than 
agar  (Bacto-agar,  Difco  Laboratories,  Detroit,  Mich.).  Transformation  fre- 
quency was reduced approximately  50% in  medium containing 0.3% agar. 
Dilution  Curve  for  A-MuLV Transformation.  The agarose suspension assay 
was used to determine the relationships  of  A-MuLV  fibroblast  focus-forming 
units to lymphoid focus-forming units.  Bone marrow cells  were infected  with 
serial  dilutions  of  A-MuLV  and plated  in agarose suspension cultures.  Macro- 
scopically  visible  colonies  of  transformed cells  were counted 12 days postinfec- 
tion.  Enumeration of  the  loci  at  various  virus  dilutions  showed  that  the  number NAOMI  ROSEN-BERG  AND  DAVID  BALTIMORE  1457 
FIG. 2.  Cells  from an A-MuLV  transformed focus  showing typical  lymphoid morphology. 
Note the mitotic  figure  (Wright-Giemsa  × 400). 
TABLE  I 
Agarose Transformation Assay Conditions 
Transformation 
Serum concentration 
Mercaptoethanol concentration 
Polybrene concentration 
% 
20%  100 
15%  68 
10%  45 
500  /~M  1 
100  /~M  54 
50  /~M  100 
10  /~M  16 
5  /~M  <0.2 
1  /~M  0 
0  0 
8  /~g/ml  100 
4  /~g/ml  100 
0  20 
Bone marrow cells from NIH/Swiss mice were infected with A-MuLV under 
quantitative conditions. The  maximum number of foci obtained under the 
various regimen was taken as 100%. 1458  ABELSON  VIRUS  LYMPHOID  CELL  TRANSFORMATION  ASSAY 
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Virus  dilution 
Fro.  3.  Dilution curve of A-MuLV. Bone marrow cells were infected with serial dilutions 
of A-MuLV and plated under quantitative conditions. Foci were scored 12 days postinfec- 
tion. 
of  foci was linearly related to the virus concentration (Fig. 3). Approximately l0  s 
fibroblast focus-forming  units were required to produce a focus of  lymphoid cells. 
Numbers of foci on replicate plates or in duplicate experiments normally varied 
less than 20%. 
Susceptibility  of Different Mouse Strains  to A-MuLV.  Bone marrow cells 
from different strains of mice vary in susceptibility to A-MuLV-induced trans- 
formation and can be classified as giving a high, medium, or low response to the 
virus (Table II). NIH/Swiss and BALB/c bone marrow cells were most suscepti- 
ble to A-MuLV. Bone marrow cells from DBA/2J, DBA/1J, and nude mice on an 
NIH/Swiss background were very resistant to A-MuLV in vitro. In most cases, 
the foci arising in DBA/2J, DBM1J, or nude mouse cultures were abnormally 
small, and attempts to serially passage foci from DBM2J and DBA/1J cultures 
have been unsuccessful. 
Presence of A-MuLV in Transformed Clones.  The association of the focus- 
forming and plaque-forming components of A-MuLV with foci of transformed 
cells was monitored by plating the colonies directly onto indicator monolayers of 
NIH/3T3  cells.  Foci of transformed NIH/3T3 cells were scored 13-15 days after 
plating at which time the plates were treated with XC cells in standard fashion. 
Both  large and small foci were tested.  Under the assay conditions a  small 
percentage of both the large and small lymphoid foci grew continuously. Most 
lymphoid cells died within 48 h  of plating on the NIH/3T3  cells. In cultures 
where the lymphoid cells were growing, both NIH/3T3  foci and plaques were 
found in 66% of dishes with large foci and 100% of dishes with small foci (Table 
III).  In cultures where the lymphoid foci did not grow both NIH/3T3  foci and 
plaques were found in 60% of dishes with large foci and 50% of dishes with small 
foci. 10% of cultures lacking growing lymphoid cells were negative for foci but 
had XC cell plaques. No dishes containing replicating lymphoid cells lacked foci 
but showed plaques. Dishes containing foci but no plaques were not found and 
would not be expected because A-MuLV is helper dependent. 
Presence  of A-MuLV-Susceptible  Cells  in  Lymphoid  Tissues.  Lymphoid NAOMI  ROSEN-BERG  AND  DAVID  BALTIMORE  1459 
TABLE  II 
Susceptibility of Mouse Bone Marrow to Transformation 
Susceptibility  Mouse strain 
High, >30 foci/108 cells  NIH/Swiss 
BALB/c 
A/J 
C57L/J 
Medium, 5-30 foci/10  e  cells  C57BL/6 
C57BR/cdJ 
NZB/BINJ 
SWR/J 
Low, <5 foci/10  8 cells  DBA/2J 
DBA/1J 
nu/nu (NIH/Swiss) 
Bone marrow cells from 3-5-wk-old  mice were infected with A-MuLV under 
quantitative conditions.  Susceptibility was evaluated based on at least two 
experiments with each strain. 
TABLE  Ill 
Recovery of A-MuL V from Transformed Clones 
Replicating clones  Nonreplicating clones 
Clone size  Focus-forming*  Plaque-forming  Focus-forming  Plaque-forming 
virus  virus  virus  virus 
Large  4/6  4/6  20/30  26/30 
Small  2/2  2/2  9/18  10/18 
Virus was detected by plating the lymphoid clones on NIH/3T3 cells using the standard A-MuLV 
focus assay and XC plaque assay. 
* Number of clones positive for virus/total clones. 
organs from fetal and adult mice were infected with A-MuLV under standard 
conditions. Foci were scored 12 days postinfection. Adult splenocytes, but not 
thymocytes, were susceptible to A-MuLV. Fetal liver cells could also be trans- 
formed using the agaroso assay. Splenocytes were more resistant to A-MuLV 
than either fetal liver or bone marrow cells (Table IV). 
Morphologic studies of the cells in the foci from spleen and fetal liver cultures 
could not distinguish these cells from those appearing in A-MuLV-infected  bone 
marrow cultures. Colonies arising in spleen and fetal liver cultures could be 
transferred to RPMI-1640 medium and maintained by serial passage. 
BSA Gradient Fractionation.  Bone marrow cells were fractionated on dis- 
continuous BSA gradients to study the distribution of  A-MuLV-sensitive cells in 
the population. Cells were harvested in PBS medium, centrifuged at low speed, 
and resuspended in 17%  BSA before layering on the gradient. Cell viability 
remained in excess of 90% throughout the procedure as monitored by exclusion 
oftrypan blue. Recovery  of  cells from the gradient was greater than 80% in most 
experiments. The distribution of nucleated cells and A-MuLV-sonsitive cells is 
shown in Fig. 4. Most of the A-MuLV-sensitive cells occarred in fractions 4 and 1460  ABELSON  VIRUS  LYMPHOID  CELL  TRANSFORMATION  ASSAY 
TABLE  IV 
Susceptibility  of Lymphoid Tissues to A-MuLV 
Tissue  Focill0  8  cells 
Bone marrow  40-60 
Fetal liver  40-60 
Spleen  10-20 
Thymus  0 
A representative experiment in which single  cell  suspensions from all 
tissues were infected with A-MuLV  and plated under quantitative 
conditions.  Foci were scored 12 days after  infection. 
40 --e-  % Transformation 
--  -.0-% Cell recovory  .~"'~ 
~  3o 
~ ao 
~-  ~o 
o 
1+2  3  4  5  6  7  B 
Cell fraction 
FIG.  4.  A-MuLV transformation of bone marrow cells fractionated on BSA gradients. 
Values are averages of six experiments. 
5. The majority of nucleated cells were found in fractions 5 and 6 overlapping the 
distribution of A-MuLV-sensitive cells. 
Discussion 
We have described here a  quantitative assay for transformation of lymphoid 
cells by the A-MuLV. The assay exploits the earlier observation that A-MuLV 
can induce indefinite growth in mass cultures of fetal liver cells (9). Using the 
focal transformation assay, we have shown that target cells for A-MuLV exist in 
mouse bone marrow and spleen as well as in fetal liver, but are absent from the 
thymus. 
The  assay  gives  a  linear  response  to  dilution  of an  A-MuLV  stock.  This 
behavior shows that the potential target cells in bone marrow are not saturated 
by our most concentrated A-MuLV stock. A minimum of 100-150 target cells]10  s 
nucleated bone marrow cells are present in some mice. The linearity of the assay 
also shows that either one particle is sufficient to give a  transformed focus or 
that  the  stocks contain  such  a  huge  excess of helper virus that  the assay is 
always saturated for the second virus. We consider it unlikely that the assay is 
saturated by the helper because the M-MuLV in our stocks is only two to five- 
fold excess, and therefore, we conclude that infection with defective A-MuLV by 
itself is able to give rise to a  focus. The existence of transformed cells not pro- 
ducing focus-forming virus (Table III) is consistent with this interpretation. 
The presence of A-MuLV-susceptible cells in fetal liver,  bone marrow,  and 
spleen,  but not in thymus,  suggests that  A-MuLV transforms  cells that  are 
related to B cells. Abelson disease does not involve the thymus (1), and A-MuLV 
has been shown to cause B-cell tumors under certain conditions (3,  16). NAOMI  ROSENBERG  AND  DAVID  BALTIMORE  1461 
The A-MuLV-sensitive cells are likely to be primitive, relatively undifferen- 
tiated cells, similar to the B-cell precursors detected in fetal liver, bone marrow, 
and spleen by others (17-19). The reduced number of A-MuLV-sensitive cells in 
spleen, which has been shown to contain fewer undifferentiated  cells than bone 
marrow or fetal liver (20), also suggests that A-MuLV transforms a relatively 
undifferentiated  cell. The inability to detect immunoglobulin on most of the A- 
MuLV-transformed cells or on A-MuLV-induced tumors (3,  9) without highly 
specific radiolabeling techniques (4) indicates that most of the transformed cells 
are not differentiated to any degree. The cells sensitive to A-MuLV in spleen, 
bone marrow, and fetal liver are likely to be similar to one another. The ability 
to transform only certain populations of cells in vitro may reflect the in vivo 
situation and indicates that tumor development is controlled in part by the 
virus' ability to interact only with a select group of cells. 
The possibility that more than one type of  cell is stimulated to focus formation 
after A-MuLV infection can not be completely eliminated. Not all foci can be 
maintained by serial passage. A proportion of  these failures can be attributed to 
low cell number and poor cell viability. Functional differences  between colonies 
may exist even though morphologic studies indicate a relatively uniform cell 
type. 
The virus-producing status of the foci vary. A significant number of the foci 
produce no detectable focus-forming or plaque-forming virus.  Studies are in 
progress to determine if these cells contain rescuable A-MuLV. The presence of 
a  small number of clones in which only the plaque-forming component of A- 
MuLV was detected probably reflects the low number of viable cells in the 
culture and the usual balance of focus-forming and plaque-forming virus pro- 
duced by A-MuLV-infected cells.  None of the foci that replicate continuously 
produce only plaque-forming virus. 
Studies with bone marrow cells from different strains of mice revealed a range 
of sensitivity of the cells to A-MuLV. Differences between highly susceptible 
cells, such as those from NIH/Swiss or BALB/c mice, and resistant cells, i.e. 
those from DBAJ2J  or DBA/1J,  are most striking. Abelson and Rabstein  (1) 
reported that DBAJ2 mice were quite susceptible to Abelson disease. In contrast, 
they found that C57BL/6 mice, whose cells are moderately sensitive to A-MuLV 
in vitro, are most resistant to A-MuLV. These data suggest that susceptibility of 
mice to Abelson disease is only partially controlled at the level of lymphoid cell- 
A-MuLV interaction, but how an animal with resistant cells can be sensitive to 
the virus in vivo must be investigated further. 
Summary 
A  quantitative  Abelson murine leukemia virus  (A-MuLV)  lymphoid cell 
transformation assay has been developed using a  semisolid agarose culture 
system. Under these conditions lymphoid cell transformation  was shown to vary 
linearly with the dose of A-MuLV used. The susceptibility of bone marrow cells 
from different strains of mice to A-MuLV-induced transformation can be esti- 
mated using the agarose assay. Strains with bone marrow cells of high, me- 
dium, and low susceptibility to A-MuLV can be identified. The assay has been 
used to study the susceptibility of cells from lymphoid organs of fetal and adult 1462  ABELSON  VIRUS  LYMPHOID  CELL  TRANSFORMATION  ASSAY 
mice to A-MuLV.  Cell suspensions  from fetal liver, adult bone marrow,  and 
adult spleen are susceptible to A-MuLV,  while thymocytes are resistant to A- 
MuLV-induced  transformation. Bovine serum albumin gradient fractionation of 
bone marrow cells  before infection with A-MuLV  demonstrates  that the major- 
ity of  A-MuLV-sensitive  cells  are recovered in a bread band partially overlap- 
ping the majority of  the nucleated cells.  The agarose assay system allows study 
of A-MuLV-lymphoid  cell interaction  at the level of single cell-single virus 
particle interaction. 
We are  grateful  to  Dr. P. C. Kung for  his  advice on  the  use of  bovine serum albumin gradients. 
Received for publication 9 February 1976. 
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